Journal articleEur Rev Med Pharmacol Sci2018
Serum miR-629 is a novel molecular marker for diagnosis and the prognosis of pancreatic cancer.
- Journal
- Eur Rev Med Pharmacol Sci
- Published
- 1 August 2018
- Citations
- 17
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Objective Increasing evidence indicates that dysregulation of miRNAs is involved in tumor progression and development. We aimed to determine potential values of miR-629 as a serum diagnostic and prognostic biomarker in pancreatic cancer (PC). … Excerpt only: this text is the publisher’s. Read it in full at the source.